Pancreatic Cancer Research

ResearcherUniversity of Colorado Cancer CenterActive in the last 2 years

Sana D. Karam

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1676-5967; OpenAlex author ID A5025056006. Sources: ClinicalTrials.gov.

Their work

Papers
12 (first author 2, last author 5)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
39
Papers, trials and grants by year

2016: 1 trial · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 3 papers · 2022: 2 papers · 2023: 5 papers · 2024: 2 papers

Papers 12

  1. Adjuvant Chemotherapy With or Without Radiotherapy for Resected Pancreatic Cancer After Multiagent Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-024-15157-4↗
  2. ASO Author Reflections: Is There a Role for Selective Adjuvant Radiotherapy in the Modern Era of Pancreatic Cancer Treatment? First author DOI 10.1245/s10434-024-15297-7↗
  3. Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis. Last author DOI 10.1016/j.ccell.2023.04.001↗
  4. Vasculitis, CA19-9, and Perineural Invasion Differentially Predict Response and Surgical Outcome in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.ijrobp.2022.12.039↗
  5. Phase 1 Dose Escalation Study of SBRT Using 3 Fractions for Locally Advanced Pancreatic Cancer. First author DOI 10.1016/j.ijrobp.2023.03.036↗
  6. Advances in the management of pancreatic cancer. Co-author DOI 10.1136/bmj-2022-073995↗
  7. Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment. Co-author DOI 10.1158/2767-9764.crc-23-0065↗
  8. Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Cancer Database cohort analysis. Co-author DOI 10.1093/bjs/znac002↗
  9. Targeting Treg-Expressed STAT3 Enhances NK-Mediated Surveillance of Metastasis and Improves Therapeutic Response in Pancreatic Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-21-2767↗
  10. Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleoti… Last author DOI 10.1007/s00262-020-02701-w↗
  11. Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study. Co-author DOI 10.1093/bjs/znab092↗
  12. Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-20-3892↗

Trials 1

  1. A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer Principal investigator NCT02873598↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marco Del Chiaro · 9 shared papers, 2021–2024 · strength 1.53
  2. Richard David Schulick · 7 shared papers, 2021–2024 · strength 1.09
  3. Wells A. Messersmith · 6 shared papers, 2021–2023 · strength 0.82
  4. Miles Piper · 6 shared papers, 2021–2023 · strength 0.77
  5. Karyn A. Goodman · 5 shared papers, 2021–2023 · strength 0.55
  6. Oskar Franklin · 2 shared papers, 2024 · strength 0.54
  7. Toshitaka Sugawara · 2 shared papers, 2023–2024 · strength 0.49
  8. Adam Christopher Mueller · 3 shared papers, 2021–2022 · strength 0.30
  9. Shuichi Watanabe · 2 shared papers, 2022–2023 · strength 0.30
  10. Alexis Diane Leal · 2 shared papers, 2021–2023 · strength 0.25
  11. Christopher Hanyoung Lieu · 2 shared papers, 2021–2023 · strength 0.25
  12. Ana Gleisner · 2 shared papers, 2021–2022 · strength 0.24
  13. Atsushi Oba · 2 shared papers, 2021–2022 · strength 0.24
  14. Michael James Gough · 2 shared papers, 2021 · strength 0.19
  15. Ayman J. Oweida · 2 shared papers, 2021 · strength 0.19
  16. Kirk Charles Hansen · 2 shared papers, 2021 · strength 0.19
  17. Bernard L. Jones · 1 shared paper, 2023 · strength 0.15
  18. Amita Shukla‐Dave · 1 shared paper, 2023 · strength 0.15
  19. Carla Hajj · 1 shared paper, 2023 · strength 0.15
  20. Zhigang Zhang · 1 shared paper, 2023 · strength 0.15
  21. Marsha Reyngold · 1 shared paper, 2023 · strength 0.15
  22. Carlo Marchetti · 1 shared paper, 2023 · strength 0.15
  23. Jesús Amo‐Aparicio · 1 shared paper, 2023 · strength 0.15
  24. Abraham Jing-Ching Wu · 1 shared paper, 2023 · strength 0.15
  25. Robert William Lentz · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.